Behind the Paper

MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application

Breast Cancer, PI3K/PTEN/AKT signaling pathway, microRNAs, Natural Products, Potential drugs.
Published in Cancer
Go to the profile of MD SADIKUJ JAMAN
MD SADIKUJ JAMAN
BIOCHEMIST, University of Rajshahi
Like
Go to the profile of India Ambler
Go to the profile of Alice Taylor

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

Share with...

...or copy the link

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Read the paper

SpringerLink
SpringerLink SpringerLink

MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application - Breast Cancer Research and Treatment

Background Globally, Breast Cancer (BC) is the most frequent cancer in women and has a major negative impact on the physical and emotional well-being of its patients as well as one of the most common cancers to be diagnosed. Numerous studies have been published to identify various molecular pathways, including PI3K/AKT/PTEN. Moreover, growing evidence suggests that miRNAs have been found to play a vital role in the growth and carcinogenesis of tumors. Because of their crucial in the development and course of the illness, all other molecular variables, molecular pathways and microRNAs have gained recognition as important therapeutic targets in BC due to growing interest among researchers in utilizing synthetic drugs and natural products to target these signaling pathway with encouraging outcomes in vivo, in vitro and preclinical trials in recent years. Methods We searched PUBMED, Science Direct, google scholar, Embase and Scopus for article published from the inception of each database to May 30, 2024. Results We discussed PI3K/PTEN/AKT signaling pathway and microRNA activities with breast cancer cell line. In addition, this review covered a wide range of potential drug and natural products as targeted therapies that are linked to downregulating ER-α expression and activity, inhibiting proliferation, migration, metastasis and angiogenesis, inducing apoptosis, cell cycle arrest and sensitizing breast cancer cells. Many studies have been conducted, but as of right now, there are not enough articles to fully explain the treatment and research of breast cancer. Conclusions We also need more and more studies on breast cancer from a variety of perspectives. Future scientist will find it easier to consider breast cancer treatment after reading this article presentation. So, the review focuses on our understanding of the roles that microRNA and PI3/PTEN/AKT signaling pathways play in regulating BC. Furthermore, we emphasized the potential therapeutic benefits of newly discovered inhibitors and the use of natural compounds in alone or combinations during preclinical trials.

Background

Globally, Breast Cancer (BC) is the most frequent cancer in women and has a major negative impact on the physical and emotional well-being of its patients as well as one of the most common cancers to be diagnosed. Numerous studies have been published to identify various molecular pathways, including PI3K/AKT/PTEN.  Moreover, growing evidence suggests that miRNAs have been found to play a vital role in the growth and carcinogenesis of tumors. Because of their crucial in the development and course of the illness, all other molecular variables, molecular pathways and microRNAs have gained recognition as important therapeutic targets in BC due to growing interest among researchers in utilizing synthetic drugs and natural products to target these signaling pathway with encouraging outcomes in vivo, in vitro and preclinical trials in recent years.

Methods

We searched PUBMED, Science Direct, google scholar, Embase and Scopus for article published from the inception of each database to May 30, 2024.

Result

We discussed PI3K/PTEN/AKT signaling pathway and microRNA activities with breast cancer cell line. In addition, this review covered a wide range of potential drug and natural products as targeted therapies that are linked to downregulating ER-α expression and activity, inhibiting proliferation, migration, metastasis and angiogenesis, inducing apoptosis, cell cycle arrest and sensitizing breast cancer cells. Many studies have been conducted, but as of right now, there are not enough articles to fully explain the treatment and research of breast cancer.

Conclusion

We also need more and more studies on breast cancer from a variety of perspectives. Future scientist will find it easier to consider breast cancer treatment after reading this article presentation. So, the review focuses on our understanding of the roles that microRNA and PI3/PTEN/AKT signaling pathways play in regulating BC. Furthermore, we emphasized the potential therapeutic benefits of newly discovered inhibitors and the use of natural compounds in alone or combinations during preclinical trials.

Go to the profile of MD SADIKUJ JAMAN
MD SADIKUJ JAMAN
BIOCHEMIST, University of Rajshahi

I am interested in using Cancer and Molecular Biology and cellular response with molecular Mechanism to understand and model the biology of cancer and to develop methods to effectively deploy therapeutic agents in the age of molecularity guided medicine. Members of my lab or all of my coauthors use a combination of conventional molecular biology.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Sign In Register

Follow the Topic

Breast Cancer
Life Sciences > Biological Sciences > Cancer Biology > Cancers > Breast Cancer

Related Collections

With collections, you can get published faster and increase your visibility.

Cancer Disparities

In line with the UN Sustainable Development Goal to Reduce Inequalities (SDG10), this collection aims to bring together articles enhancing our understanding of cancer health disparities across the different dimensions of inequality research.

There are many expanding fields of health inequalities research but this collection will include articles examining disproportionate cancer burdens in populations such as: rural-urban, gender/sexual, racial/ethnic, religious minority and socioeconomic status groups, and of course any group where health inequality needs to be addressed.

This wider collection builds upon our existing collections more specifically focused on 'Racial and ethnic disparities in cancer' and 'Racial and ethnic disparities in cancer in the US'.

We are building an ongoing knowledge base of content from across oncology journals to increase the discoverability of articles in this important research area. Thus, we call for new contributions to this collection and invite you to read recent research below.

We also wish to highlight a related webinar recording 'Roundtable on Black in cancer research and oncology'.

Editors for Supportive Care in Cancer: Dr Devon Check and Prof Janet de Groot

Editors for Prostate Cancer and Prostatic Diseases: Dr Samuel L. Washington III, Dr Jun Luo, Dr Yaw Nyame, Dr Randy Vince Jr and Dr Jennifer Beebe-Dimmer

Please note that other journals participating in the collection do not have specific Guest Editors appointed and manuscripts are handled on a case by case basis by members of our editorial boards.

Publishing Model: Hybrid

Deadline: Ongoing

Explore this collection

Artificial Intelligence in Breast Imaging

Artificial intelligence (AI) is becoming integrated into many aspects of our day -to -day life, whether its suggestions on movies we should consider, books we may be interested in reading or apparel that may suit our personal taste. In preclinical research, AI provides tools for rapid and robust evaluation of cancer cell and organoid phenotypes or data from small animal imaging. AI is particularly well suited to radiology where it affords opportunities to enhance the speed, accuracy and quality of image interpretation. Rather than eliminating the need for radiologists anytime soon, AI can serve as a valuable adjunct to them allowing resulting in more dependable interpretations of ever more complex technology used in radiology. However, integration of AI to clinical imaging workflows requires careful evaluation of associated ethical, legal, and regulatory challenges.

In this cross-journal collection, we welcome a wide range of articles on AI in breast imaging, including primary research articles, method-based articles, reviews, and perspectives. To express your interest to contribute, please contact the Editor-in-Chief of the respective journal:

Journal of Mammary Gland Biology and Neoplasia: Zuzana Koledova (koledova@med.muni.cz)

Breast Cancer Research & Treatment: William J. Gradishar (w-gradishar@northwestern.edu)

Breast Cancer Research: Lewis A. Chodosh (chodosh@pennmedicine.upenn.edu)

Publishing Model: Hybrid

Deadline: Ongoing

Explore this collection

Latest Content

Cookies

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.

Further information can be found in our privacy policy.

Cookie Control

Customise your preferences for any tracking technology

The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.

See the full cookie policy See the full privacy policy
More information

These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.

More information

These trackers help us to deliver personalized marketing content and to operate, serve and track ads.

More information

These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.

More information

These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.

More information

These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.